Asset Management One Co. Ltd. Boosts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Asset Management One Co. Ltd. raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,918 shares of the medical research company’s stock after buying an additional 315 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Charles River Laboratories International were worth $3,522,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CRL. Wellington Management Group LLP grew its holdings in Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after buying an additional 3,738,018 shares during the period. Mizuho Securities USA LLC grew its holdings in Charles River Laboratories International by 2,336.4% in the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock valued at $19,081,000 after buying an additional 92,895 shares during the period. Premier Fund Managers Ltd grew its holdings in Charles River Laboratories International by 56.3% in the 3rd quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company’s stock valued at $49,573,000 after buying an additional 90,000 shares during the period. JPMorgan Chase & Co. grew its holdings in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after buying an additional 85,759 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after buying an additional 47,221 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

CRL stock opened at $165.00 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $275.00. The stock’s 50 day moving average is $174.02 and its two-hundred day moving average is $188.99. The company has a market capitalization of $8.44 billion, a PE ratio of 20.65, a P/E/G ratio of 5.91 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period in the previous year, the business earned $2.46 EPS. Charles River Laboratories International’s revenue for the quarter was down 1.1% compared to the same quarter last year. Analysts predict that Charles River Laboratories International, Inc. will post 10.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on CRL shares. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research note on Monday, February 3rd. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Morgan Stanley reduced their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Finally, The Goldman Sachs Group reduced their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of “Hold” and an average target price of $197.64.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).